Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

2 Dec 2015

Abstract excerpt

PURPOSE: Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models and extend the knowledge on the role of BRD4 in MYCN-driven neuroblastoma. EXPERIMENTAL DESIGN: The efficacy of OTX015 was assessed in in vitro and in vivo models of human and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Neuroblastoma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26631615
DOI: 10.1158/1078-0432.ccr-15-1449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionPMID 26631615Read ↗

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionSemantic proximity Read ↗

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targetsSemantic proximity Read ↗

Epigenetic Dysregulation in MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified NeuroblastomaSemantic proximity Read ↗

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastomaSemantic proximity Read ↗

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in NeuroblastomaSemantic proximity Read ↗

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targetsSemantic proximity Read ↗

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseasesSemantic proximity Read ↗

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaSemantic proximity Read ↗

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsSemantic proximity Read ↗

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.